Abingdon Health plc (LON:ABDX), a manufacturer of lateral flow diagnostic tests, has entered into a strategic partnership agreement with in vitro diagnostics specialist Senzo Health Limited, the two companies announced on Monday.
Under this agreement Abingdon Health will provide contract development and manufacturing (CDMO) services to Senzo and its partners to enable them to develop and manufacture new rapid tests utilising Senzo's Amplified Lateral Flow (ALF) point-of-care diagnostics platform technology.
Senzo's lateral flow technology is designed to deliver the same accuracy as laboratory-based PCR with results available within 10 minutes, at a fraction of the cost.
It is initially being applied to the development of a COVID-19 antigen assay, a broader respiratory panel and other infectious disease tests, with potential future applications across clinical, animal health, food, plant pathogen and environmental testing. The new partnership will allow Senzo's partners to accelerate product development through access to Abingdon Health's CDMO services.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer